We found that compared to grade I–II gliomas, grade III–IV gliomas exhibited relatively higher SLC19A1 expression (Supplementary Figure S2A), suggesting a potential role of SLC19A1 in promoting the malignant progression of gliomas. Here, SLC19A1 is linked to central nervous system cancer.